Compugen (CGEN) Registration filing summary

Company overview and business model

• Clinical-stage therapeutic discovery and development company focused on cancer immunotherapy using an AI/ML-powered computational platform, Unigen™.

• Pipeline includes four clinical-stage programs: COM701, COM902, rilvegostomig (licensed to AstraZeneca), and GS-0321 (licensed to Gilead).

• Business model centers on selective collaborations and revenue-sharing arrangements for novel targets and drug candidates.

• Integrates computational capabilities with immuno-oncology research to advance drug targets from prediction to clinical trials.

Financial performance and metrics

• As of March 31, 2026: $134.9 million in cash and equivalents, $95.4 million in total shareholders' equity.

• 94,584,636 ordinary shares issued and outstanding, with additional shares reserved for options and incentive plans.

Use of proceeds and capital allocation

• Net proceeds from securities sales intended for operations, working capital, capital expenditures, acquisitions, collaborations, R&D, and debt repayment.

• Management retains broad discretion over allocation; proceeds may be invested in capital preservation instruments pending use.